Company profile
LYELL IMMUNOPHARMA, INC.
NASDAQ:LYELBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RONDECABTAGENE AUTOLEUCEL | phase3 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06153095 | phase1_2 | withdrawn | 2024-02-15 | 2025-01-09 | Lyell Immunopharma, Inc. | A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) |
| NCT05274451 | phase1 | terminated | 2022-03-29 | 2024-11-27 | Lyell Immunopharma, Inc. | A Study to Investigate LYL797 in Adults With Solid Tumors |
| NCT05573035 | phase1 | terminated | 2022-12-19 | 2025-01-09 | Lyell Immunopharma, Inc. | A Study to Investigate LYL845 in Adults With Solid Tumors |
| NCT07188558 | phase3 | recruiting | 2026-01-12 | 2029-12-01 | Lyell Immunopharma, Inc. | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy |
| NCT05319314 | phase1_2 | recruiting | 2022-08-01 | 2028-06-01 | Lyell Immunopharma, Inc. | LYL273 for Patients With Relapsed or Refractory mCRC |
FDA applications (0)
No records yet.